The HIV/AIDS pandemic remains an important threat to human health. We have recently demonstrated that a novel microRNA (miR-128) represses retrotransposon (LINE-1 or L1) by a dual mechanism, by directly targeting the coding region of the L1 RNA and by repressing a required nuclear import factor (TNPO1). We have further determined that miR-128 represses the expression of all three isoforms of TNPO proteins (transportins, TNPO1,-2 and TNPO3). Here, we establish that miR-128 also controls HIV-1 replication by repressing TNPO3. TNPO3 is well established to regulate HIV-1 nuclear import and viral replication. Here, we report that the type I interferon inducible miR-128 directly targets two sites in the TNPO3 mRNA, significantly down-regulating TNPO3 mRNA and protein expression levels. Manipulation of miR-128 levels in HIV target cell lines and in primary human CD4 T-cells by over-expression or knockdown showed that modulation of TNPO3 by miR-128 affects HIV-1 replication but not MLV infection. In addition, we found that miR-128 modulation of HIV-1 replication is reduced with TNPO3-
INTRODUCTION

Human immunodeficiency virus (HIV) infection:
The HIV/AIDS pandemic remains an important threat to human health. To date more than 34 million people are infected with HIV. Unique characteristics make HIV-1 difficult to eradicate. HIV-1 uses and evades the immune system, replicating in and destroying immune cells during active replication. To develop novel and widely applicable strategies, a thorough understanding of the cellular determinants of HIV-1 replication and viral latency is crucial, including epigenetic changes and transcriptional and post-translational regulation (1) (2) (3) (4) (5) (6) (7) . Due to its limited genome (10 kb) HIV-1 has to rely on cellular co-factors to progress through its lifecycle. Host factors are not only needed for productive HIV-1 replication but also for latency establishment and reactivation whereas restriction factors protect the cells against infection and provide innate immunity (8) (9) (10) (11) (12) (13) (14) . miRs and their role as viral restriction factors: microRNA (miRNA or miR) biogenesis begins in the nucleus with transcription, to create the long primary miR (primiR) including a hairpin that contains the mature sequence. The hairpin is excised by the microprocessor that includes Drosha, an RNase III enzyme, and its cofactor DGCR8, producing the 60-70 nucleotide precursor miRs (pre-miR). The pre-miR is exported out of the nucleus by Exportin-5 where another RNase III enzyme, Dicer, processes the premiR into the 21-23 nucleotide duplex miR. The strand destined to be the mature sequence is then loaded onto Argonaute (Ago), forming the miR-induced silencing complex (miRISC) along with other proteins (15, 16) . Using imperfect base pairing, miRs guide RISC to specific mRNAs to down-regulate their expression by triggering mRNA destabilization or translational repression (17, 18) . miR-target recognition is often dependent on a short, six nucleotide seed sites, which perfectly complement the 5' of the miR (position 2-7) (19) . Both miRs and the mRNA binding sites are highly conserved (19, 20) . miRs exemplify the emerging view that non-coding RNAs may equal proteins in regulatory importance. The majority of the human transcriptome is predicted to be under miR regulation, positioning this post-transcriptional control pathway within every major genetic cascade (21) . miRs can regulate and coordinate development, modulate selfrenewal, differentiation and self fate establishment (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . In addition, Dicer and Drosha knock-out experiments has demonstrated that miR pathways repress HIV-1 replication and contribute to the maintenance of latency (26) . Furthermore, profiling studies suggests that miRs in general are down-regulated upon T-cell activation, suggesting increased target de-repression during optimal HIV-1 infection (27) (28) (29) . Also, miRs have been described to function in complex ways in the intersection between host and pathogen for example as an anti-viral defense mechanism and/or as a facilitator of latency (30, 31) . miRs has been proposed to negatively affect HIV-1 by directly targeting of the viral RNA genome and or by repressing virus-dependent cellular co-factors, these miRs include miR-29, -150,-28, -125b, 223 and 382 (32) . The complex interplay between miRs and their mRNA targets during HIV-1 infection, replication and latency needs further investigations.
Work in colleagues and our laboratory established that interferon-induced miRs represse viral replication of Hepatitis C Virus (HCV) (30, (33) (34) (35) . As the life cycle of long-interspaced-elements-1 (L1) mimics that of a virus, we next asked the question whether miRs also regulate L1 activity. L1 retrotransponsons and related SINE elements make up approximately 35% of the human genome, with some L1 elements still being active, regardless of multiple cellular restriction mechanisms (36) (37) (38) (39) (40) (41) . We recently performed an anti-miR lentiviral library screen to identify miRs involved in the regulation of de novo L1 retrotransposition. miR-128 was identified as a negative regulator of L1 and further characterization led to the discovery of a novel principle by which miR-128 represses de novo retrotransposition of L1 elements in somatic cells, including cancer cells, cancer stem cells and iPSCs, by directly binding L1 RNA and targeting it for degradation (42) . This finding was surprising as the most well understood mechanism by which miRs function relies on the binding and regulation by one miR to multiple cellular mRNAs, whose protein products typically function in a specific pathway within the cell. We therefore explored if miR-128 might also regulate cellular proteins involved in L1 retrotransposition. We used bioinformatics analysis in combination with miR-128 RNA immune-purification (RIP) RNA Smart sequencing approaches and identified the mRNA for a nuclear import factor (TNPO1) as a target of miR-128 binding. Our recent results (manuscript under revision) determines that TNPO1 is a functional target for miR-128, by directly targeting TNPO1 for degradation, which result in the L1 ribonucleoprotein (RNP) complex being trapped in the cytoplasm and L1 retrotransposition and genomic integration repressed. Thus miR-128 represses L1 retrotransposition by two independent mechanisms: 1) repression of a key co-factor required by L1 (TNPO1), and 2) directly binding L1 RNA (42) . The TNPO family of proteins contains, TNPO1, -2 and TNPO3. Interestingly miR-128 has predicted binding sites in all three TNPO protein isoforms.
Here we report that the type I interferon induced microRNA miR-128 regulates TNPO3 mRNA and protein expression levels in cell lines (HeLa, Jurkat, and THP-1 cells) and in primary CD4 T-cells, by directly targeting TNPO3 mRNA. Infection studies using wild-type and TNPO3-independent N74D mutant HIV-1 reporter virus demonstrate that miR-128 significantly represses HIV-1 replication in cell lines and in CD4 T-cells, and that miR-128-induced HIV-1 repression is partly dependent on TNPO3 reduction (N74D HIV-1 showing de-repression). The cleavage and polyadenylation specificity factor subunit 6 (CPSF6), one of SR proteins, is a conditional restriction factor for HIV-1, and can be transported to the nucleus by TNPO3, the nuclear importer of SR proteins.
When TNPO3 is removed from cells, CPSF6 accumulates in the cytoplasm and restricts HIV-1 infection (51). CPSF6-depletion studies show a partial rescue of HIV-1 inhibition caused by TNPO3 reduction. Finally, infection studies using replication competent HIV-1 NL4-3 virus a significant delay in viral spreading in miR-128 overexpressing Jurkat and primary CD4+ T-cells. Together these studies support the idea that when TNPO3 is disrupted (by miR-128), then CPSF6 accumulates in the cytoplasm and inhibits HIV-1 replication.
RESULTS
miR-128 regulates TNPO3 expression levels.
Three in the importin gene family, TNPO1, TNPO2 and TNPO3, contain predicted miR-128 binding sites (Supplemental Figure S1 ). This is noteworthy, as TNPO3 is required for successful nuclear import of the HIV-1 pre-integration complex (PIC) and viral replication (43) (44) (45) (46) (47) (48) (49) . As mentioned, CPSF6 is a conditional HIV-1 cofactor, aiding in nuclear steps of virus replication in cells retaining TNPO3 function (48) .
If TNPO3 is disrupted, CPSF6 accumulates in the cytoplasm and inhibits HIV-1 viral replication (49) (50) (51) (52) (53) . Of note, we and others have determined that type I interferon induces miR-128 levels, suggesting a role for miR-128 in anti-viral defense in human cells (Supplemental Figure S2 and (30,54) ). Furthermore, miR-128 is expressed in HIV-1 target cells including CD4 T-cells and blood-derived monocytes (Supplemental Figure S2 and (54-58)). Thus, if miR-128 represses expression of TNPO proteins, including TNPO3, we would predict that miR-128 represses HIV-1 replication.
To explore this possibility, we generated stably transduced miR-modulated cells lines (miR-128 overexpressing, anti-miR-128 in which endogenous miR-128 is neutralized and miR controls) of HeLa cells. We validated that miR-128 expression levels was modulated as expected and at physiological relevant levels similar to changes induced by cytokines and growth factors (30, 54) by miR specific qPCR (miR-128 was induced 4-5 fold in miR-128 overexpressing cells, while miR-128 was reduced by 40-50% in anti-miR-128 expressing HeLa cells) (Supplemental Figure S3) .
Next, we evaluated TNPO3 levels in cell lines in which miR-128 was reduced or overexpressed. The level of TNPO3 mRNA was significantly reduced in miR-128 overexpressing HeLa cells compared to miR controls, whereas TNPO3 mRNA levels were increased when miR-128 was neutralized by anti-miR-128 ( Figure 1A , left panel).
To rule out the possibility that miR-128 overexpression using a lentiviral delivery strategy itself caused reduction in TNPO3 mRNA levels, we next examined the levels of were not significant although it was not completely restored to control levels ( Figure 2C ).
These results indicate that miR-128 targets TNPO3 mRNA and both predicted seed sites are responsible for their interaction ( Figure 2C ). When correcting for the lower expression level of TNPO3 mRNA, (because of lower miR-128 expression levels), which may underestimate the scale of the effect, the relative fraction of immunopurified-Ago-bound TNPO3 mRNA significantly increased when miR-128 was overexpressed, compared to anti-miR-128 control ( Figure 2D , IP, right panel). In contrast, miR-128 did not repress GAPDH mRNA expression levels or immuno-purified GAPHD mRNA, as expected ( Figure 2E ). This result suggests that high levels of miR-128 lead to higher levels of TNPO3 mRNA being bound in Ago-complex and TNPO3 expression is regulated directly by miR-128. These data imply that miR-128 represses TNPO3 expression via a direct interaction with the target sites located in the CRS and 3'UTR of the TNPO3 mRNA. 
miR-128-induced HIV-1 inhibition is partly dependent on TNPO3.
Next, we wished to explore whether miR-128 induced-TNPO3 repression is required for HIV-1 repression. We took advantage of the N74D CA mutant single-cycle HIV-1 reporter virus pseudotyped with VSV-G (N74D NLdELuc). The single mutation at N74 in HIV-1 capsid has been shown to affect the sensitivity of HIV-1 infection to depletion of various nuclear import factors including TNPO3 (49, 62, 63) .
In order to dissect the role of miR-128-induced TNPO3 repression, we generated The cellular factor CPSF6 mostly localizes in the nucleus. Interestingly, it was shown to interact with HIV-1 CA (capsid) protein (but not the N74D mutant), and CPSF6 becomes anti-viral when it localizes in the cytoplasm (49) . As explained, when TNPO3, a carrier of SR proteins to the nucleus, is removed from cells, CPSF6 accumulates in the cytoplasm and blocks HIV-1 infection at the nuclear entry process by sequestering HIV-1 PIC associated CA (49-52) (and see Figure 4E) . Therefore, we next tested if miR-128- 
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MATERAILS AND METHODS.
Cell culture and primary HIV-1 target cell isolation
Viral Infections
Finally, activated primary CD4 T-cells were infected with HIV-1 NL4-3 (100ng/10E6) for 7 days. Supernatant were collected on day 3,5 and 7 for p24 assays. On day 7 infected cells were harvested and stained for intracellular anti-gag (clone KC57). Level of infection as presented by % gag+ is shown among GFP+ transduced cells.
Transfection and transduction
OptiMem (31985070, Lifetech) and Lipofectamine RNAiMAX (13778075, Lifetech) were used to complex and transfect 20µM miR-128 mimic, anti-miR-128 or control mimics (C-301072-01 and IH-301072-02, Dharmacon) into cells. OptiMem and Xtreme Gene HP (06366236001, Roche Lifescience) was used to transfect pJM101 neomycin L1 reporter plasmid into HeLa cells. Cells were transduced with high titer virus using polybrene (sc-134220, Santa Cruz Biotech) and spinoculation (800xg at 32˚C for 30 minutes). Transduced cells were then selected and maintained using 3µg/mL puromycin.
RNAi using shRNA against TNPO3
shRNA for TNPO3 was designed using the RNAi Consortium (https://www.broadinstitute.org/rnai/public/) using clone TRCN0000235098 and cloned into pLKO.1 puro backbone (Addgene, #8453). pLKO shGFP control plasmid was preassembled (Addgene, #30323).
Lentiviral packaging
VSVG-pseudotyped lentiviral vectors were made by transfecting 0.67µg of pMD2-G (12259, Addgene), 1.297µg of pCMV-DR8.74 (8455, Addgene), and 2µg of mZIP-miR-128, mZIP-anti-miR-128, pLKO-shControl or pLKO-shHNRNPA1 (transfer plasmid)) into 293T cells using Lipofectamine LTX with plus reagent (15338030, ThermoFisher).
Virus-containing supernatant was collected 48hr and 96hr post-transfection. Viral SUPs were concentrated using PEG-it virus precipitation solution (LV810A-1) according to manufacturer's instructions.
RNA extraction and quantification
RNA was extracted using Trizol (15596-018, ThermoFisher) and Direct-zol RNA 
Statistical analysis
Student's t-tests were used to calculate two-tailed p values and data are displayed as mean ± standard error of the mean (SEM) of technical (TR) or independent biological replicates (IBR), (n) as indicated. 
